Proven design and performance of the Valiant Captivia System now offers broader options to treat a wide range of patient anatomies.

1. Proven design with enhanced conformability and kink resistance

2. Additional components to treat a wide range of anatomies

3. Tip capture for accuracy of positioning

4. Consistent clinical performance across a variety of pathologies

The Valiant Captivia System with proximal FreeFlo tapers continues to deliver the proven performance with additional components for broad patient suitability.

> 21% OF PATIENTS IN VALOR II TRIAL (N=160) PRESENTED TAPERED AORTAS. THE VALIANT CAPTIVIA SYSTEM WITH PROXIMAL FREEFLO TAPERS HELPS YOU TREAT MORE ANATOMIES WITH CONFIDENCE.*

*Data on file at Medtronic, Inc.
CONFIDENCE IN CONTROL

The Valiant Captivia System features tip capture of the proximal stent. Tip capture provides controlled deployment and placement when navigating the thoracic aorta.

CONTROLLED DEPLOYMENT WITH TIP CAPTURE

Deployment  Captured  Released

Placement  Release

Tip capture provides accurate stent graft placement  After tip capture is released, the Valiant Captivia System conforms to the patient’s anatomy
The Valiant Captivia System is designed to conform to the thoracic aorta. The sinusoidal shape and placement of nitinol springs provide flexibility and conformability to the anatomy. The Valiant Stent Graft is the only device that maintains complete apposition regardless of angulation and oversizing.*

**Results:** The Valiant stent graft remained apposed to the aortic wall at each increment of neck angulation and degree of oversizing in a simulated environment.

For the other stent grafts tested, lack of device wall apposition was observed between the proximal anchorage segment and the inferior aortic wall.

**OPTIMIZED ACCESS**

The Valiant Captivia System features a crossing profile similar to or lower than other thoracic stent grafts. Ease of access means control at every step, across a broad range of anatomies.

**DEVICE OUTER DIAMETER PROFILES**

<table>
<thead>
<tr>
<th>Crossing Profile (OD)*</th>
<th>Medtronic Valiant®</th>
<th>Bolton Relay®</th>
<th>Cook®/Zenith® TX2® Pro-Form</th>
<th>Gore® C-TAG®</th>
</tr>
</thead>
<tbody>
<tr>
<td>24F</td>
<td>24F</td>
<td>26F</td>
<td>27F</td>
<td></td>
</tr>
<tr>
<td>Hydrophilic Coating</td>
<td>Yes</td>
<td>Yes</td>
<td>No</td>
<td>No</td>
</tr>
<tr>
<td>Sheath Required</td>
<td>No</td>
<td>No</td>
<td>Yes</td>
<td>Yes</td>
</tr>
</tbody>
</table>

System OD for Gore C-Tag® & Cook Zenith® list the OD of sheath as their IFUs recommend the use of a sheath. The System OD for Medtronic Valiant and Bolton Relay list the OD of the delivery catheter as the use of a sheath is not required per the respective IFUs.

* 36 mm diameter graft used for comparison for all manufacturers except Gore. A 37 mm diameter graft used for Gore since no 36 mm diameter graft exists.

**EASY THREE-STEP DEPLOYMENT PROCESS**

**STEP 1.**
Slow, controlled deployment for precise stent graft placement

**STEP 2.**
Quick deployment option if desired

**STEP 3.**
Tip capture release

Hydrophilic coating to facilitate stent graft delivery

TIP CAPTURE RELEASE HANDLE
Simple turn-and-pull motion for tip release

DeVic OuteR DeveLoPMeNT PRoFILeS
The Valiant Captivia System is built on Medtronic’s 15 years of thoracic stent graft experience and is proven in more than 50,000 implants. Our advanced design enhances confidence.*

1. Proximal 8-Peak FreeFlo Configuration
   Evenly distributes radial force over multiple apices

2. Figur8 Markers for Accurate Placement
   Platinum iridium markers provide high visibility

3. Enhanced Conformability
   Absence of longitudinal bar allows for enhanced flexibility and kink resistance

4. Broad Selection of Pieces
   Broad selection of proximal and distal components leads to many combinations to customize for a variety of patients

* Test data on file at Medtronic, Inc. Bench test results may not be indicative of clinical performance.
The Valiant® Captivia® system demonstrates safety and effectiveness in the treatment of acute, complicated Type B aortic dissections.

**U.S. MEDTRONIC DISSECTION TRIAL**
Prospective, non-randomized, multi-center trial

**OUTCOMES OF TEVAR IN ACUTE, TYPE B AORTIC DISSECTION: RESULTS FROM THE VALIANT® US IDE TRIAL (N=50)**

**30-DAY AND 1-YEAR RESULTS**

- The Valiant® Captivia® system demonstrates safety and effectiveness in the treatment of acute, complicated Type B aortic dissections.

**MEDTRONIC U.S. DISSECTION TRIAL**
DEMONSTRATES POSITIVE AORTIC REMODELING OF STENTED SEGMENT

<table>
<thead>
<tr>
<th>Time</th>
<th>False Lumen Volume</th>
<th>True Lumen Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>6 MTHS</td>
<td>15%</td>
<td>85%</td>
</tr>
<tr>
<td>12 MTHS</td>
<td>6%</td>
<td>94%</td>
</tr>
<tr>
<td>6 MTHS</td>
<td>3%</td>
<td>97%</td>
</tr>
<tr>
<td>12 MTHS</td>
<td>-</td>
<td>100%</td>
</tr>
</tbody>
</table>

- Decrease
- Increase
- Stable

**EVIDENCE HIGHLIGHTS**

- 8% all-cause mortality at 30D met primary safety endpoint
- 100% delivery and deployment success at implant
- 100% coverage of primary entry tear at implant
- 0% ruptures at 30 days and 12 months

Source: Valiant Captivia Instructions for Use, Summary of Clinical Studies

**THE VALIANT CAPTIVIA SYSTEM SUCCESSFULLY TREATS A BROAD RANGE OF PATHOLOGIES AND ANATOMIES**

Comprehensive clinical studies and registries now support the use of TEVAR in patients with aortic dissections.

**MEDTRONIC CLINICAL DATA SUPPORTS THE USE OF TEVAR ACROSS MULTIPLE PATHOLOGIES**

<table>
<thead>
<tr>
<th>CLINICAL TRIAL/STUDY</th>
<th># PATIENTS ENROLLED</th>
<th>TRIAL STUDY DESIGN</th>
</tr>
</thead>
<tbody>
<tr>
<td>VALOR (The Talent thoracic stent graft*)</td>
<td>195</td>
<td>Prospective, non-randomized, multi-center U.S. IDE study conducted to evaluate the safety and effectiveness of the Talent stent graft system in patients with descending thoracic aneurysms</td>
</tr>
<tr>
<td>INSTEAD:XL (The Talent thoracic stent graft)</td>
<td>140</td>
<td>Prospective, randomized controlled trial evaluating TEVAR+Optimal Medical Therapy vs Medical Therapy alone in uncomplicated Type B aortic dissections</td>
</tr>
<tr>
<td>VALOR II (The Valiant stent graft)</td>
<td>160</td>
<td>Prospective, non-randomized, multi-center U.S. IDE study conducted to evaluate the safety and effectiveness of the Valiant stent graft system in patients with descending thoracic aneurysms</td>
</tr>
<tr>
<td>VIRTUE (The Valiant stent graft)</td>
<td>100</td>
<td>Prospective, non-randomized multi-center European registry evaluating Valiant in Type B aortic dissections</td>
</tr>
<tr>
<td>VALIANT CAPTIVIA REGISTRY (The Valiant Captivia system)</td>
<td>100</td>
<td>Multi-center, non-interventional, single arm registry. Mid to high risk all comor cohort</td>
</tr>
<tr>
<td>RESCUE (The Valiant Captivia system)</td>
<td>50</td>
<td>Prospective, non-randomized, multi-center U.S. IDE trial to evaluate device performance in blunt thoracic aortic injury</td>
</tr>
<tr>
<td>Medtronic U.S. DISSECTION Trial (The Valiant Captivia system)</td>
<td>50</td>
<td>Prospective, non-randomized, multi-center U.S. IDE trial to evaluate device performance in acute, complicated Type B aortic dissections</td>
</tr>
</tbody>
</table>

*The Talent® thoracic stent graft is no longer commercially available in the U.S.*